MBX Biosciences (MBX) Receivables - Other (2023 - 2026)

MBX Biosciences has disclosed Receivables - Other across 4 years of filings, most recently posting $3.2 million for Q1 2026.

• Receivables - Other for Q1 2026 came in at $3.2 million, up 127.94% year-over-year; the trailing twelve-month figure through Mar 2026 was $3.2 million (up 127.94% YoY), and the FY2025 annual result was $2.1 million, up 210.85% from the prior year.
• Receivables - Other came in at $3.2 million for Q1 2026 at MBX Biosciences, up from $2.1 million in the prior quarter.
• In the past five years, Receivables - Other ranged from a high of $3.2 million in Q1 2026 to a low of $208000.0 in Q4 2023.
• The 4-year median for Receivables - Other is $1.1 million (2024), against an average of $1.3 million.
• Across the five-year window, Receivables - Other soared 227.88% in 2024 and surged 80.42% in 2025, its largest moves.
• MBX Biosciences' Receivables - Other stood at $208000.0 in 2023, then jumped by 227.88% to $682000.0 in 2024, then surged by 210.85% to $2.1 million in 2025, then soared by 48.92% to $3.2 million in 2026.
• The last three Receivables - Other figures came in at $3.2 million (Q1 2026), $2.1 million (Q4 2025), and $1.5 million (Q3 2025), per Business Quant data.